Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Meneldor is a venture capital organization based in the Netherlands, established to support early-stage biotech and pharmaceutical companies. Founded by industry specialists, Meneldor provides investors the opportunity to invest alongside experts in this complex sector. The firm conducts thorough assessments of potential portfolio companies, evaluating factors such as scientific soundness, intellectual property, medical needs, market potential, competition, management, financial requirements, and valuation before making investment decisions.
Currently, Meneldor manages a portfolio of five companies, focusing on innovations that address significant unmet medical needs. The firm operates primarily in Western Europe, leveraging its expertise to identify promising projects in the biotech and pharmaceutical fields. Meneldor's commitment to rigorous evaluation and specialized knowledge positions it as a key player in the early-stage investment landscape.
Meneldor primarily invests in early-stage biotech and pharmaceutical companies that are developing new biological or chemical molecular entities. The organization targets projects in preclinical, Phase I, or Phase II stages, particularly those with clear clinical endpoints. Meneldor seeks companies that address significant unmet medical needs and possess strong intellectual property, ensuring that investments are made in ventures with high potential for success.
The firm’s geographic focus is on Western Europe, allowing it to tap into a rich pool of innovative biotech startups. Meneldor emphasizes collaboration with specialists in the sector, providing a unique opportunity for investors to engage with cutting-edge developments in healthcare. The firm’s investment strategy is designed to support companies that are not only scientifically sound but also commercially viable, enhancing the likelihood of successful outcomes.
Meneldor's current portfolio includes five notable companies:
These companies exemplify Meneldor's commitment to investing in innovative solutions that address critical healthcare challenges.
Paul Lelieveld, Ir., MSc. - Founding Partner. Paul has extensive experience in the biotech sector and has led numerous successful investments in early-stage companies.
Frans van Dalen, Pharm. D. - Founding Partner. Frans brings a strong pharmaceutical background, having worked in various capacities within the industry, focusing on drug development and commercialization.
Mark Buscher - Intellectual Property Expert. Mark specializes in intellectual property rights and has a proven track record in protecting innovations within the biotech field.
Peter Goedings, Dr. - Senior Clinical Expert. Peter has significant experience in clinical trials and regulatory affairs, providing valuable insights to portfolio companies.
Cees Stouten, MSc. - Senior Drug Development & Manufacturing Expert. Cees has a strong background in drug development processes and manufacturing, assisting startups in scaling their operations effectively.
To pitch Meneldor, founders should send an email to info@meneldor.nl. It is recommended to include a comprehensive deck that outlines the project, including scientific background, market analysis, and financial projections. Meneldor appreciates detailed information that demonstrates the potential impact of the innovation.
Response times may vary, but founders should expect to hear back within a few weeks. Warm introductions are preferred, as they can facilitate a more favorable review process.
What are Meneldor's investment criteria?
Meneldor focuses on early-stage biotech and pharmaceutical companies that are developing new biological or chemical molecular entities. The firm looks for projects in preclinical, Phase I, or Phase II stages with clear clinical endpoints and strong intellectual property.
How can I pitch to Meneldor?
Founders can reach out via email at info@meneldor.nl. It is advisable to include a detailed overview of the project, including scientific background, market potential, and financial projections.
What makes Meneldor different from other investors?
Meneldor emphasizes collaboration with specialists in the biotech sector, providing unique insights and support to portfolio companies. The firm conducts thorough assessments to ensure investments are made in scientifically sound and commercially viable projects.
What is Meneldor's geographic focus?
The firm primarily invests in companies located in Western Europe, allowing it to leverage local expertise and market knowledge.
What is the typical check size for investments?
While specific check sizes are not disclosed, Meneldor invests at the pre-seed, seed, and seed-plus stages, indicating a focus on early-stage funding.
What kind of support does Meneldor provide to portfolio companies?
Meneldor offers operational support, access to industry expertise, and guidance on navigating the complexities of the biotech sector, enhancing the chances of success for its portfolio companies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.